Kezar Life Sciences
4000 Shoreline Ct
Suite 300
South San Francisco
94080
United States
Tel: 650-822-5600
Website: http://www.kezarlifesciences.com/
Email: contact@kezarbio.com
About Kezar Life Sciences
Founded in 2015 and based in South San Francisco, Kezar (pronounced “keys are”) Life Sciences is combining courage, conviction and cutting-edge science to develop breakthrough treatments for immune-mediated and oncologic disorders – with the hope of helping people overcome their disease and live a better life. We are pioneering first-in-class, small molecule therapies that harness master regulators of cellular function to inhibit multiple drivers of disease via single, powerful targets. We are translating our innovative research in protein degradation (via immunoproteasome inhibition) and protein secretion (via the Sec61 translocon) to have a significant clinical impact in the most difficult-to-treat diseases.
Stock Symbol: $KZR
For the second year in a row, Kezar Life Sciences was named one of the Best Places to Work in the Bay Area by The San Francisco Business Times! If you are passionate about helping people overcome disease and live better lives, consider joining our amazing team.
65 articles with Kezar Life Sciences
-
Kezar Life Sciences stock rose 92% after it announced positive topline results from its Phase II clinical trial investigating the use of zetomipzomib for the treatment of Lupus Nephritis (LN).
-
Kezar Life Sciences Announces Positive Topline Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib for the Treatment of Patients with Lupus Nephritis
6/27/2022
Kezar Life Sciences, Inc. (Nasdaq: KZR), today reported positive topline results from the MISSION Phase 2 clinical trial evaluating zetomipzomib, a novel, first-in-class selective immunoproteasome inhibitor, in patients with active lupus nephritis (LN).
-
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - June 03, 2022
6/3/2022
Kezar Life Sciences, Inc. announced that the Compensation Committee of the company’s Board of Directors granted three employees nonqualified stock options to purchase an aggregate of 12,000 shares of its common stock with an exercise price of $4.86 per share, which is equal to the closing price of Kezar’s common stock on June 1, 2022, the grant date of the awards.
-
Kezar Life Sciences Reports First Quarter 2022 Financial Results and Provides Business Update
5/12/2022
Kezar Life Sciences, Inc. reported financial results for the first quarter ended March 31, 2022 and provided a business update.
-
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - May 05, 2022
5/5/2022
Kezar Life Sciences, Inc. announced that the Compensation Committee of the company’s Board of Directors granted two employees nonqualified stock options to purchase an aggregate of 29,000 shares of its common stock with an exercise price of $12.54 per share, which is equal to the closing price of Kezar’s common stock on May 2, 2022, the grant date of the awards.
-
Kezar Announces Topline Results from PRESIDIO Trial of Zetomipzomib for the Treatment of Dermatomyositis and Polymyositis
5/3/2022
Kezar Life Sciences, Inc. announced topline results from the PRESIDIO Phase 2 clinical trial of zetomipzomib in patients with dermatomyositis and polymyositis.
-
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
4/15/2022
Kezar Life Sciences, Inc today announced that the company’s Board of Directors has granted one employee a nonqualified stock option to purchase 100,000 shares of its common stock with an exercise price of $15.44 per share.
-
Kezar Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Update
3/17/2022
Kezar Life Sciences, Inc., (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today reported financial results for the fourth quarter and year ended December 31, 2021 and provided a business update.
-
Kezar Life Sciences to Participate in Cowen 42nd Annual Health Care Conference
3/2/2022
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that Noreen Roth Henig, M.D., Chief Medical Officer, will participate on the Kidney Disease/Fibrosis Panel at the Cowen 42nd Annual Health Care Conference.
-
Kezar Appoints Courtney Wallace to its Board of Directors
12/10/2021
Kezar Life Sciences, Inc today announced the appointment of strategic business development executive Courtney Wallace to its Board of Directors.
-
Kezar Life Sciences Announces Interim Results from the MISSION Phase 2 Trial in Patients with Lupus Nephritis
11/15/2021
Kezar Life Sciences, Inc. (Nasdaq: KZR), today reported interim results from the Phase 2 portion of its MISSION clinical trial evaluating KZR-616, a first-in-class selective immunoproteasome inhibitor, in patients with active, proliferative lupus nephritis (LN).
-
Kezar Life Sciences to Present at the Jefferies London Healthcare Conference
11/11/2021
Kezar Life Sciences, Inc. today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference. The presentation will be available for on-demand viewing starting Thursday, November 18 at 3:00 a.m. EST.
-
Kezar Reports Third Quarter 2021 Financial Results and Provides Business Update
11/9/2021
Kezar Life Sciences, Inc., a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, reported financial results for the third quarter ended September 30, 2021 and provided a business update.
-
Kezar to Host Virtual Investor and Analyst Day on November 15, 2021
11/3/2021
Kezar Life Sciences, Inc. today announced that it will host a virtual Investor and Analyst Day on November 15, 2021, at 4:30 p.m. ET.
-
Kezar Announces First Patient Dosed in Phase 1 Trial of KZR-261 in Advanced Solid Tumor Malignancies
10/27/2021
Kezar Life Sciences, Inc. today announced that the first patient has been dosed in KZR-261-101, a Phase 1 clinical trial evaluating KZR-261, a novel, broad-spectrum, anti-tumor agent that acts through direct interaction and inhibition of the Sec61 translocon.
-
Variety, passion and the ability to make tangible improvements in people’s lives have propelled John Fowler, co-founder and CEO of Kezar Life Sciences, throughout his career.
-
Kezar Life Sciences Appoints Gitanjali Jain as Vice President, Investor Relations and External Affairs
10/5/2021
Kezar Life Sciences, Inc., a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, announced the appointment of Gitanjali Jain as Vice President, Investor Relations and External Affairs.
-
Kezar Life Sciences to Participate in Two Upcoming Investor Conferences in September 2021
9/2/2021
Kezar Life Sciences, Inc., a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, announced members of the executive team will participate in the following upcoming virtual investor conferences.
-
Kezar Life Sciences Announces Completion of Enrollment of Its Phase 2 PRESIDIO Clinical Trial of KZR-616 in Polymyositis and Dermatomyositis
8/23/2021
Kezar Life Sciences, Inc., a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, announced that PRESIDIO, its Phase 2 clinical trial to evaluate the safety and efficacy of KZR-616 for the treatment of polymyositis and dermatomyositis completed the target enrollment of 24 subjects.
-
Kezar Life Sciences Reports Second Quarter 2021 Financial Results and Provides Business Updates
8/12/2021
Kezar Life Sciences, Inc., a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, announced its second quarter 2021 financial results and corporate highlights.